Welcome to CORRONA

The Consortium of Rheumatology Researchers of North America, Inc. (CORRONA) was founded in 2000 by leading rheumatologists dedicated to advancing and improving the care of patients with rheumatic diseases. CORRONA's mission is to advance rheumatology research and improve the quality of rheumatology patient care. CORRONA is an independent registry without any ownership links to the pharmaceutical industry. It is run by a group of experienced academic and clinical rheumatologists throughout the country with a wide range of experience (see CORRONA Leadership link).

Data on Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Osteoporosis, and Osteoporosis Risk derived from rheumatologists and patients are entered from the site where the physician saw the patient. The data are entered in the aggregate from around the United States and can then be analyzed by members of the CORRONA team. Data from the CORRONA registry can be used to derive insights regarding the effectiveness, and safety of drugs used to treat these diseases. It can also be used for the purposes of improved patient care and quality management.

CORRONA's Goal

The goal of CORRONA is to construct a community of Rheumatologists where by collecting data we can ethically architect a database that will help those with RA/PsA. It is through this collection of patient data that we can hope to achieve an opportunity for quality of life for others.

CORRONA offers qualified clinical sites the opportunity to take part in the data collection process. CORRONA is looking to secure data on patients that you already have in your practice and to be compensated for baseline visits, follow up visits, changes in biologics and reporting of adverse events.

CORRONA asks each potential site to assign a PI to this endeavor and you can include as many MD/Extenders (PA/NP) as you would like (Extenders must have patient contact and also be able to complete a tender and swollen joint count.) We would need a copy of all CV’s and medical licenses and for each site to complete the IRB (Institutional Review Board) application. Once a site is approved by CORRONA, we will cover the fee associated with the IRB, we will then implement the CORRONA study at your location. All data will be directly entered at each corresponding site.

As our commitment to clinical sites is evident in our communication with them (Newsletter, Practice Management and Efficiency, Audit Protection tools, etc) we also ask the same of each potential site. Each site should commit to greater than 80% of follow up for enrolled patients in the study. It is this follow up data that will allow us to consistently move forward and progress in the treatment outcomes of rheumatoid arthritis.